BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230130
DTEND;VALUE=DATE:20230202
DTSTAMP:20260516T045527
CREATED:20221121T083953Z
LAST-MODIFIED:20221121T083953Z
UID:35900-1675036800-1675295999@www.pharmajournalist.com
SUMMARY:3rd TGF-β for Immuno-Oncology Drug Development Summit
DESCRIPTION:Exploit Understanding of TGF-β Biology\, Harness Clinically Validated Biomarkers & Advance Safe & Efficacious Clinical Programs for Maximal Therapeutics Benefit in Immuno-Oncology. \nIn the past year alone\, the field has learnt valuable lessons from the clinical trials and from the wider TGF-β field that will equip the immuno-oncology field with the knowledge needed to supercharge future TGF-β monotherapy or combinational therapeutics for precision medicine. \nFrom uncovering the effects and production of TGF-β in immune\, tumor and stromal cells to exploring predictive and pharmacodynamic TGF-β biomarkers for patient identification and assessing the clinical challenges that led to recent clinical failures\, the 3rd TGF-β for Immuno-Oncology Drug Development Summit is your one-stop-shop dedicated to harnessing you with the knowledge to unlock the potential of successfully targeting TGF-β. \nTailored with 18+ senior leaders\, the 2023 meeting will be taking place in-person for the first time – don’t miss your chance to be in the room for your comprehensive guide on TGF-β in immuno-oncology! \nWhether you are new to this field or a seasoned expert\, this meeting will provide you with the must-know takeaways from the basic biology to biomarkers to clinical trial design to overcome the clinical setbacks and produce a blockbuster TGF-β therapeutic. \nTo know more visit: https://ter.li/cjnpgy
URL:https://www.pharmajournalist.com/event/3rd-tgf-%ce%b2-for-immuno-oncology-drug-development-summit/
LOCATION:Marines Memorial Club and Hotel\, 609 Sutter St\, San Francisco\, CA\, 94102\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230202
DTEND;VALUE=DATE:20230203
DTSTAMP:20260516T045527
CREATED:20221208T120155Z
LAST-MODIFIED:20221208T120155Z
UID:36005-1675296000-1675382399@www.pharmajournalist.com
SUMMARY:Cancer Neoantigen Vaccines
DESCRIPTION:Over the last few decades\, immunotherapy has developed at a rapid rate in the treatment of cancer where neoantigens are the latest breakthrough in tumour immunotherapy. Today\, it is still unclear when a cancer vaccine will be made commercially available; what is the latest academic research showing us? What is the industry missing and where are we going? \nJoin us through a series of inspiring keynote presentations and engaging panel discussions to connect with top pioneers in the space\, to discuss the future of cancer immunotherapy and how neoantigens are transforming the field. \nUnlock the new era of vaccine development at Cancer Neoantigen Vaccines\, a 1-day digital conference taking place February 2\, 2023 and discover the path to commercial success with novel approaches toward cancer neoantigen vaccines. \nYou’ll shape the future of next generation cancer vaccine development with new oncolytic approaches and critical immunotherapy strategies and uncover\, key research on targets and evolution\, how to successfully enter global markets and the future of personalisation and beyond. \nYou can expect to uncover methods of identifying true targets and deep dive into the future of machine and deep learning in identifying neoantigens. Plus\, you’ll hear successful case studies and promising data on the latest neoantigen vaccine development and gain a deeper understanding of the future of vaccines in personalised medicine. Don’t miss your opportunity to be a part of the discussions with industry experts on their look to the future. \nAll of this plus much more without leaving your desk! Your digital pass gives you access to the full attendee list with video chat\, instant message\, and meeting request functionalities to connect with like-minded thought-leaders in the field to expand your network\, and access to the content on-demand for 10 working days post-event.
URL:https://www.pharmajournalist.com/event/cancer-neoantigen-vaccines/
LOCATION:Digital Conference
ORGANIZER;CN="Informa Connect":MAILTO:Danielle.horney@informa.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230208
DTEND;VALUE=DATE:20230210
DTSTAMP:20260516T045527
CREATED:20221025T104610Z
LAST-MODIFIED:20221025T104610Z
UID:35615-1675814400-1675987199@www.pharmajournalist.com
SUMMARY:14th Annual RNA Therapeutics Conference
DESCRIPTION:SAE Media Group invites you to join the 14th Annual RNA Therapeutics Conference\, taking place on 8 and 9 February 2023\, in London\, UK. \nBuilding on the success of previous years\, the RNA Therapeutics Conference will bring together industry experts from leading pharma and biotech companies to provide an expert and holistic view on the latest developments of the industry. \nRNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy\, personalised medicines\, and treatment of genetic\, infectious and chronic diseases. This is reflected with the value of the global antisense & RNA therapeutics market expected to reach USD 1.81 billion by 2025\, growing at a CAGR of 7.5%. \nWith Covid-19 rapidly accelerating the RNA landscape through massive regulatory successes\, the recent advent of CRISPR\, an RNA-guided gene-editing technology\, as well as new strides in the delivery of messenger RNA transcribed in vitro\, there has been considerable progress in the development of RNA medicines and a major expansion of the RNA-therapeutics field. \nThis year’s conference will reflect on how the industry has adapted and played a pivotal role in global health over the past year and will discuss the takeaways for future mRNA therapeutic development. \nBenefits of attending: \n\nExplore how mRNA leads the way in the genetic medicine space as the next generation of novel drug modalities\nInvestigate the latest trends in AI drug discovery as a tool for designing novel RNA based therapeutics\nEnhance your knowledge of the latest innovations in RNA application and RNA delivery techniques with case studies from BioNTech\, Neuway Pharma and Ethris GmbH\nEngage in the growing advances and development of novel RNA molecules in the treatment of chronic respiratory\, neurodegenerative\, and infectious diseases\n\nWho should attend: \n\nDirectors of novel RNA therapies\nCEOs\nSenior and expert scientists\nChief Medical Officers\nChief Technical Officers\nSenior Vice Presidents\nGlobal Heads of mRNA R&D\nGlobal Medical Directors\nHeads of Translational Medicine\nDirector\, Clinical Pharmacology\nGlobal Head of RNA and Targeted Therapeutics\nClinical Science Director\nHead of Biology\nDirector\, Genetic Medicine\nAssociate Director\n\nEARLY-BIRD RATES: \n\nREGISTER BY 31ST OCTOBER AND SAVE £400\nREGISTER BY 3OTH NOVEMBER AND SAVE £200\nREGISTER BY 16TH DECEMBER AND SAVE £100
URL:https://www.pharmajournalist.com/event/14th-annual-rna-therapeutics-conference/
LOCATION:Copthorne Tara Hotel\, Scarsdale Place\, Kensington\, London\, W8 5SY\, United Kingdom
ORGANIZER;CN="SAE Media Group":MAILTO:lamprini.balasi@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230208
DTEND;VALUE=DATE:20230210
DTSTAMP:20260516T045527
CREATED:20221117T082926Z
LAST-MODIFIED:20221117T082926Z
UID:35834-1675814400-1675987199@www.pharmajournalist.com
SUMMARY:Healthcare Payment & Revenue Integrity Summit
DESCRIPTION:Introducing the only industry forum exclusively bringing together key decision-makers\, within health insurers and providers\, who are responsible for payment and revenue integrity\, value-based payment\, and networking relations. \nAt a time when both payers and providers are evaluating and streamlining internal payment and revenue integrity processes\, this networking conference has been established to breakdown silos\, by promoting discussion between clinical\, coding\, revenue cycle and payment departments to facilitate the development of efficient\, value-based healthcare systems. \nTo know more visit: https://healthcarepaymentrevenueintegritysummit.com
URL:https://www.pharmajournalist.com/event/healthcare-payment-revenue-integrity-summit/
LOCATION:ORLANDO\, FLORIDA
ORGANIZER;CN="Kisaco Research":MAILTO:marketing@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230208
DTEND;VALUE=DATE:20230210
DTSTAMP:20260516T045527
CREATED:20221128T102920Z
LAST-MODIFIED:20221128T103039Z
UID:35931-1675814400-1675987199@www.pharmajournalist.com
SUMMARY:6th Annual 3D Cell Culture Conference
DESCRIPTION:6th Annual 3D Cell Culture Conference \n8-9 February 2022 \nLondon\, UK\nhttp://www.3D-cellculture.com/PJwl \nSponsored: CelVivo\, Promega and Systemic Bio \nConference Co-chairs: \nPhillip Hewitt\, Global Head of Early Investigative Toxicology\, Merck \nRhiannon David\, Director\, Microphysiological Systems\, AstraZeneca  \nExploring the implementation of complex in-vitro models for drug development \nJoin us in February 2023\, as SAE Media Group’s 6th annual 3D Cell Culture Conference brings together industry experts from big pharma\, regulatory bodies\, and cutting-edge researchers to discuss the challenges and drivers of these medical technologies\, through case studies of the latest innovations in 3D Cell Culture models\, real world examples of clinical applications\, and insights into regulatory validation and high throughput screening to give a comprehensive look into this fast growing industry. \n3D Cell Culture has gained increasing momentum in the pharmaceutical industry over recent years\, with the global 3D Cell Culture market predicted to reach a value of $3.48 Billion by 2028. The pharmaceutical industry globally is realising the growing potential of in vitro tissue models for drug discovery\, pathology modelling and validation\, safety and toxicity. 3D Cell Culture technology promises to offer increased translatability in models and reduce the costly rates of drug attrition in the discovery process — heralding the next major advance in the discovery of pharmaceuticals. \nEvent Hashtag: #3DCellCulture2023 \nKey Conference Highlights: \n\nDiscuss the uses of advanced cell technologies for human tissue bioengineering\nUncover the major benefits of 3D modelling in enhancing clinical translation and predictability\nUtilise 3D cell culture for personalised drug screening and high-throughput screening over traditional 2D methods\nLearn how to implement 3D Cell Culture techniques for antibody and cell and gene therapy discovery process\nDelve into advanced case studies looking into organ models: from the blood-brain barrier to liver spheroids\n\nWho Should Attend? \nBiotech / Pharma Companies – Investigative toxicologist\, Research Scientist\, Clinical Pharmacologist\, Cell Technologists\, Cell and Molecular Scientist\, Head of Translational Research\,  In-Vitro Toxicologists\,  Director of Drug Discovery\, Head of DMPK\, Chief Scientific Officer\,  R&D Scientist\, Head of R&D. \nAcademia – Cell Technology\, Stem Cell Sciences\, Biochemistry\, Protein Technology and Tissue Engineering \nSolution Providers – Manager\, Head of\, CEO\, Director\, Founder\, Account Manager\, President\, CSO\, Executive\, Managing Director\, Vice President\, COO\, Biomedical Engineers\, Head of External Collaboration \nOrganisations / Regulatory – Director\, Senior Science Advisor\, Scientific Officer\, Advisor for Toxicology
URL:https://www.pharmajournalist.com/event/6th-annual-3d-cell-culture-conference/
LOCATION:London\, UK
ORGANIZER;CN="SAE Media Group":MAILTO:simi.sapal@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230214
DTEND;VALUE=DATE:20230217
DTSTAMP:20260516T045527
CREATED:20221027T104008Z
LAST-MODIFIED:20221027T104008Z
UID:35627-1676332800-1676591999@www.pharmajournalist.com
SUMMARY:CRISPR AgBio Congress 2023
DESCRIPTION:The 5th Annual CRISPR AgBio Congress will unite research heads\, molecular biologists\, regulatory experts\, and product developers from large Ag companies\, innovative AgBiotechs\, academic groups and regulatory bodies to translate share the challenges and opportunities of translating cutting-edge CRISPR technology into a tangible product. If you are working to advance genome-edited crops or plants\, this is the must-attend meeting to network with the leading stakeholders progressing the space forward\, keep up with the latest technology advances & guidances\, and ensure your product is set up to help meet the significant food security challenges the world is currently facing. \nTo know more visit: https://ter.li/3nrx25
URL:https://www.pharmajournalist.com/event/crispr-agbio-congress-2023/
LOCATION:The Westin San Diego Bayview\, 400 W Broadway\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230221
DTEND;VALUE=DATE:20230224
DTSTAMP:20260516T045527
CREATED:20221027T104330Z
LAST-MODIFIED:20221027T104330Z
UID:35633-1676937600-1677196799@www.pharmajournalist.com
SUMMARY:Retinal Vascular Disease Drug Development Summit
DESCRIPTION:Retinal Vascular Disease Drug Development Summit is an event dedicated to creating a community space dedicated to overcoming the current challenges in drug development for retinal vascular diseases. \nThe management of these diseases has made remarkable advancements in previous years\, but the burden on patients remains high\, posing a need to develop novel therapeutics and delivery mechanisms that improve the efficacy and durability of anti-VEGF drugs and beyond. \nProviding you with an in-depth coverage of technical insights of anti-VEGF\, innovative non-VEGF targeting therapeutics for wet-AMD\, DME\, DR and RVO\, the Retinal Vascular Disease Drug Development Summit will address the specific challenges in utilizing preclinical models for retinal vascular disease\, understand key regulatory requirements\, and learn how to run effective clinical trials that utilize appropriate endpoints. \nJoin your colleagues from across R&D\, preclinical\, translational and clinical teams across the biopharmaceutical industry to streamline your drug development and address the significant and increasing unmet medical need. \nTo know more visit: https://ter.li/7xp7xc
URL:https://www.pharmajournalist.com/event/retinal-vascular-disease-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230221
DTEND;VALUE=DATE:20230223
DTSTAMP:20260516T045527
CREATED:20221102T085213Z
LAST-MODIFIED:20221102T085213Z
UID:35698-1676937600-1677110399@www.pharmajournalist.com
SUMMARY:6th CAR-TCR Summit Europe
DESCRIPTION: Join us in London this February to connect with those trailblazing the next wave of CAR and TCR based approaches from pre-clinical development with in vivo engineering and regulatory fast-track strategies to streamlined analytics and automation to make CAR and TCR therapies better\, and faster. \n \nTake advantage of cutting-edge innovation from global biopharma leaders in cell armouring\, combination approaches and multiplexing gene engineering to improve cell durability and trafficking across allogeneic and solid tumour indications\, and leave understanding the technical strategies to build automated\, closed-system manufacturing processes to ensure vein to vein time is less than a week. \nPromising data-driven case studies outlining next generation product design\, clinical trial set-up and manufacturing processes\, this meeting is your go-to to comprehensively assess the emerging improvements of CAR and TCR based therapies.  \nSee the full agenda here: https://ter.li/ulbn8o
URL:https://www.pharmajournalist.com/event/6th-car-tcr-summit-europe/
LOCATION:ExCeL London\, Royal Victoria Dock\, 1 Western Gateway\, London\, E16 1XL\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230221
DTEND;VALUE=DATE:20230224
DTSTAMP:20260516T045527
CREATED:20221124T112536Z
LAST-MODIFIED:20221124T113110Z
UID:35914-1676937600-1677196799@www.pharmajournalist.com
SUMMARY:3rd Annual Gene Therapy for Muscular Disorders Summit
DESCRIPTION:The past twelve months have seen an unprecedented level of excitement\, investment\, and progression within the gene therapy for muscular disorders field. As the industry endeavours to move gene therapy treatment through the preclinical and clinical pipeline\, in context of reducing toxicity and increasing efficacy\, attending the 3rd Annual Gene Therapy for Muscular Disorders Summit has never been so crucial. \nThis year’s summit will return to Boston to reunite 100+ leading experts in biotech\, pharma and academia to continue to develop strategies to deliver safer and more effective gene therapies to muscle cells. \nThis summit will encompass all aspects of preclinical development and highlight the obstacles in clinical trials\, enabling you to address and overcome these challenges. \nTo know more visit: https://ter.li/wi2a51
URL:https://www.pharmajournalist.com/event/3rd-annual-gene-therapy-for-muscular-disorders-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230221
DTEND;VALUE=DATE:20230224
DTSTAMP:20260516T045527
CREATED:20230202T105848Z
LAST-MODIFIED:20230202T105848Z
UID:36454-1676937600-1677196799@www.pharmajournalist.com
SUMMARY:11th Alzheimer’s & Parkinson’s DD Summit
DESCRIPTION:Welcome to the 11th Alzheimer’s & Parkinson’s Drug Development Summit \n \nWith a surge in preclinical investment\, fresh news of clinical pipeline progressions\, and a new era of therapies pending FDA approvals from Biogen\, Eisai\, and Denali Therapeutics\, 2022 has put neurodegenerative drug development back on the map. \nBuilding on the field’s momentum\, we are delighted to bring back the 11th Alzheimer’s & Parkinson’s Drug Development Summit\, dedicated to overcoming the translational challenges of targeting neurodegenerative mechanisms. This summit will unite neurodegenerative biopharma experts from discovery\, preclinical\, translational\, and clinical backgrounds to showcase the latest breakthroughs in Alzheimer’s\, Parkinson’s\, and related neurological disorders in 2022 and 2023 \nTo know more visit: https://ter.li/x0w74p
URL:https://www.pharmajournalist.com/event/11th-alzheimers-parkinsons-dd-summit/
LOCATION:Hyatt Centric Fisherman’s Wharf\, San Francisco\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:Info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230222
DTEND;VALUE=DATE:20230224
DTSTAMP:20260516T045527
CREATED:20221205T103427Z
LAST-MODIFIED:20221205T103427Z
UID:35996-1677024000-1677196799@www.pharmajournalist.com
SUMMARY:2nd Next Generation Kinase Inhibitors Summit
DESCRIPTION:Since Kinase inhibitors have proven to be efficacious and approvable targets\, fuelling recent investment into this exciting space as their therapeutic targeting is explored beyond oncology. However\, increasing resistance to existing programs and safety bottlenecks threaten further progress. The next wave of kinase targets depends on innovation. \nJoin the 2nd Next Generation Kinase Inhibitors Summit to connect with experts across discovery\, R&D\, and clinical medicine to discuss how to accelerate the next generation of kinase inhibitor drugs to market\, which displays maximal therapeutic efficacy and durable clinical responses. \nKey Topics: \n\nAssay Development\, Kinome Exploration & and Kinase-Focussed Drug Discovery Principles\nOvercoming Tumor Resistance\, Managing the Tumor Microenvironment\, and Improving Durability\nExploiting the RAS/MAPK Signalling Pathway\nMultikinase and Combination Therapies to Overcoming Resistance\nTargeting Established Pharmacological Mechanisms in Alternative Indications Beyond Oncology to Meet Unmet Needs\n\nDon’t miss this opportunity to join & network with 100+ Kinase Biology Experts under one roof\, hear from 18+ expert speakers from the space and showcase your work at the Scientific Poster Session. \nThis meeting is FREE for drug developers and researchers! \nTo know more visit: https://ter.li/sreltb
URL:https://www.pharmajournalist.com/event/2nd-next-generation-kinase-inhibitors-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR